Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

February 2, 2026
2 min

The Ophthalmologist

Objective:

To report the FDA approval of YUVEZZI™, a dual-agent eye drop for treating presbyopia in adults.

Approach:

Key Findings:

YUVEZZI demonstrated superiority over its individual components in BRIO I.
In BRIO II, it achieved significant improvements in near visual acuity for up to eight hours.
Safety study included over 72,000 treatment days with no serious adverse events reported.

Interpretation:

The approval of YUVEZZI represents a significant advancement in non-invasive options for managing presbyopia, addressing patient needs for convenience and flexibility.

Limitations:

Long-term effects beyond the study duration are not yet known.
The trials primarily focused on short-term efficacy and safety.

Conclusion:

YUVEZZI's dual-mechanism approach and once-daily dosing may provide a valuable alternative for patients seeking pharmacologic correction of near vision.